Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced data from the Phase Ib part of its Phase Ib/II European study of the molecularly targeted anti-cancer drug, ADH-1, which is being presented at the 2006 American Society of Clinical Oncology Annual Meeting, a major international cancer conference (Abstract No. 3042, poster display/discussion session 8 a.m.-1 p.m.).
